PDS Biotechnology Corpora... (PDSB)
NASDAQ: PDSB
· Real-Time Price · USD
1.22
0.02 (1.67%)
At close: Aug 15, 2025, 1:23 PM
1.67% (1D)
| Bid | 1.2 |
| Market Cap | 55.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.5M |
| EPS (ttm) | -0.91 |
| PE Ratio (ttm) | -1.34 |
| Forward PE | -1.28 |
| Analyst | Buy |
| Ask | 1.22 |
| Volume | 247,318 |
| Avg. Volume (20D) | 605,046 |
| Open | 1.22 |
| Previous Close | 1.20 |
| Day's Range | 1.18 - 1.25 |
| 52-Week Range | 0.85 - 4.29 |
| Beta | 0.95 |
About PDSB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PDSB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PDSB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-0.63%
PDS Biotechnology shares are trading higher after ...
Unlock content with
Pro Subscription
5 months ago
-8.21%
PDS Biotechnology shares are trading higher after the company announced the initiation of its VERSATILE-003 Phase 3 clinical trial.
3 months ago · proactiveinvestors.co.uk
EMV Capital portfolio company PDS Biotech advances cancer trialPDS Biotechnology Corporation (NASDAQ:PDSB), a US cancer immunotherapy firm backed by EMV Capital (AIM:EMVC), has begun site activations for its phase III trial of Versamune HPV in patients with head ...